Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

This review aims to provide an extensive overview of the literature on the clinical
pharmacokinetics of mycophenolate in solid organ transplantation and a briefer summary of …

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

Annually, about 8000 heart and lung transplantations are successfully performed worldwide.
However, morbidity and mortality still pose a major concern. Renal failure in heart and lung …

A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide
immunosuppression with mycophenolate mofetil was held in New York in December 2004 …

The impact of CYP3A and MDR1 gene single‐nucleotide polymorphisms on long‐term
tacrolimus disposition and drug‐related toxicity has not been assessed. A study was …

Therapeutic drug monitoring (TDM) for tacrolimus (Tac) is universally applied. However, the
concentration–effect relationship for Tac is poorly defined. This study investigated whether …

AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal
transplant recipients. Background Tacrolimus has a narrow therapeutic window, and …

The immunosuppressive agent mycophenolate is used extensively in kidney transplantation,
yet dosing strategy applied varies markedly from fixed dosing (“one-dose-fits-all”), to …

The aim of this study was to develop a population pharmacokinetic model of tacrolimus in
pediatric kidney transplant patients, identify factors that explain variability, and determine …